Elite Pharmaceuticals, Inc.

ELTP · OTC
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income-$4,315$20,109$3,562$8,898
Dep. & Amort.$2,122$1,472$1,345$1,435
Deferred Tax$3,795-$19,989$1,509,616-$2,172
Stock-Based Comp.$228$8,514$579$781
Change in WC-$15,166-$11,881-$2,026-$1,010
Other Non-Cash$20,792-$1,506-$1,509,738-$1,424
Operating Cash Flow$7,456-$3,282$3,339$6,508
Investing Activities
PP&E Inv.-$1,625-$810-$5,737-$499
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$775$0$0$0
Investing Cash Flow-$2,400-$810-$5,737-$499
Financing Activities
Debt Repay.-$845$3,339$1,702-$667
Stock Issued$19$159,921$39,325$14,353
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$46$0$0
Financing Cash Flow-$826$3,386$1,702-$667
Forex Effect$0$0-$695,019$0
Net Chg. in Cash$4,230-$706-$696$5,343
Supplemental Information
Beg. Cash$7,539$8,245$8,940$3,598
End Cash$11,769$7,539$8,245$8,940
Free Cash Flow$4,931-$4,091-$2,398$6,010